Widespread debate erupted several weeks ago when a pharmaceutical start-up bought and raised the price of a 60-year-old drug by 5,000 percent. In the face of public backlash, the company’s CEO agreed to a reduced price. And when a San Diego-based company introduced a $1 alternative, patients and the media alike celebrated. But the incident has fueled a broader public debate about the cost and value of prescription medications.
More at Institute for Patient Access